Sector Gamma AS Sells 12,676 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Sector Gamma AS reduced its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,490 shares of the biopharmaceutical company’s stock after selling 12,676 shares during the quarter. Ultragenyx Pharmaceutical accounts for about 1.2% of Sector Gamma AS’s investment portfolio, making the stock its 27th largest holding. Sector Gamma AS owned about 0.12% of Ultragenyx Pharmaceutical worth $4,901,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. UMB Bank n.a. increased its holdings in shares of Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Covestor Ltd increased its holdings in shares of Ultragenyx Pharmaceutical by 392.1% in the third quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 596 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 3,182.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 1,623 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 97.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 903 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Ultragenyx Pharmaceutical by 38.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock worth $95,000 after buying an additional 548 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on RARE shares. Robert W. Baird upped their price objective on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Wedbush reissued a “neutral” rating and set a $48.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, April 16th. Royal Bank of Canada started coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Canaccord Genuity Group raised their price objective on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. raised their price objective on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $88.08.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $201,922.56. Following the transaction, the executive vice president now owns 67,340 shares in the company, valued at approximately $3,620,198.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John Richard Pinion sold 4,173 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the transaction, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock worth $1,645,983 in the last 90 days. Company insiders own 6.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE traded up $0.39 during trading hours on Friday, reaching $44.24. 450,422 shares of the stock were exchanged, compared to its average volume of 704,581. The firm has a market capitalization of $3.64 billion, a price-to-earnings ratio of -5.31 and a beta of 0.65. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $54.98. The stock’s fifty day simple moving average is $47.80 and its 200 day simple moving average is $43.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.13. The company had revenue of $127.39 million for the quarter, compared to analyst estimates of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.16) earnings per share. Research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.